## Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee October 9, 2003

## **Bibliography**

## AM Session

- 1. Frost, B-M. Pharmacokinetics of Doxorubicin in Children With Acute Lymphoblastic Leukemia: Multi-Institutional Collaborative Study. Med Pediatr Oncol. 2002; 38:329-337.
- 2. Groninger, E, et al. **Pharmacokinetics of Vincristine Monotherapy in Childhood Acute Lymphoblastic Leukemia**. Ped Rsch. 2002;2(1):113-118.
- 3. Hempel, G, et.al. **Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma**. Canc Chemother and Pharm. 2001
- 4. Nath, CE. **Population pharmacokinetics of amphotericin B in children with malignant diseases**. J Clin Pharmacol. 2001; 52:671-680.

## **PM Session**

- 5. Pawar, S. and Kumar, A. Issues in the Formulation of Drugs for Oral Use in Children Role of Excipients. Pediatr Drugs. 2002; 4(6):371-379.
- 6. Nahata, MC. **Pediatric Drug Formulations: Challenges and Potential Solutions**. Annals of Pharmacother. Feb 1999; 33:247-249.
- 7. Kovarik, JM, et.al. Clinical Development of an Everolimus Pediatric Formulation: Relative Bioavailability, Food Effect, and Steady-State Pharmacokinetics. J Clin Pharmacol. 2003;43:141-147.